Trastuzumab deruxtecan efficacy, FcRn-facilitated penetration of the blood-tumor barrier and distribution to tumor cells in HER2+ brain metastasis model systems
{{output}}
Background: Trastuzumab deruxtecan (T-DXd) is an antibody-drug conjugate (ADC) approved for metastatic HER2+ and HER2-low/ultralow breast cancer. It has shown impressive clinical activity for HER2+ brain metastases. We conducted ... ...
